Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Melnick

Showing results (1-10 of 230) with videos related to

Pageof 23
Sort By:
Cancer Cell|November 17, 2012
Epigenetic therapy leaps ahead with specific targeting of EZH2Ari Melnick
Cell Cycle (Georgetown, Tex.)|January 19, 2005
Reprogramming specific gene expression pathways in B-cell lymphomasAri Melnick
Hematology. American Society of Hematology. Education Program|December 17, 2008
Transitioning from fellowship to a physician-scientist career trackAri Melnick
Cancer Discovery|May 10, 2013
Discovering what makes STAT signaling TYK in T-ALLLorena Fontan, Ari Melnick
Cancer Discovery|November 3, 2018
Untangling the Role of Polycomb Complexes in Chemotherapy ResistanceCihangir Duy, Ari Melnick
Expert Review of Hematology|September 3, 2013
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?Leandro Cerchietti, Ari Melnick
Seminars in Hematology|March 26, 2015
The epigenetic basis of diffuse large B-cell lymphomaYanwen Jiang, Ari Melnick
Current Opinion in Hematology|May 18, 2011
Epigenetics and B-cell lymphomaRita Shaknovich, Ari Melnick
Current Cancer Drug Targets|January 8, 2021
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)Yusuke Isshiki, Ari Melnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
DNA Methylation-Based BiomarkersLeandro Cerchietti, Ari Melnick
Pageof 23

Showing results (1-10 of 230) with videos related to

Sort By:
Pageof 23
Cancer Cell|November 17, 2012
Epigenetic therapy leaps ahead with specific targeting of EZH2Ari Melnick
Cell Cycle (Georgetown, Tex.)|January 19, 2005
Reprogramming specific gene expression pathways in B-cell lymphomasAri Melnick
Hematology. American Society of Hematology. Education Program|December 17, 2008
Transitioning from fellowship to a physician-scientist career trackAri Melnick
Cancer Discovery|May 10, 2013
Discovering what makes STAT signaling TYK in T-ALLLorena Fontan, Ari Melnick
Cancer Discovery|November 3, 2018
Untangling the Role of Polycomb Complexes in Chemotherapy ResistanceCihangir Duy, Ari Melnick
Expert Review of Hematology|September 3, 2013
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?Leandro Cerchietti, Ari Melnick
Seminars in Hematology|March 26, 2015
The epigenetic basis of diffuse large B-cell lymphomaYanwen Jiang, Ari Melnick
Current Opinion in Hematology|May 18, 2011
Epigenetics and B-cell lymphomaRita Shaknovich, Ari Melnick
Current Cancer Drug Targets|January 8, 2021
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)Yusuke Isshiki, Ari Melnick
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
DNA Methylation-Based BiomarkersLeandro Cerchietti, Ari Melnick
Pageof 23